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Sequence analysis has shown significant homology between the catalytic regions of the mammalian ras
GTPase-activating protein (GAP), yeast Iralp and Ira2p (inhibitory regulators of the RAS-cyclic AMP
pathway), and neurofibromin, the protein encoded by the NFl gene. Yeast expression experiments have
confirmed that a 381-amino-acid segment of neurofibromin, dubbed the GAP-related domain (GRD), can
function as a GAP. Using the RNA polymerase chain reaction with primers flanking the NFI-GRD, we have
identified evidence for alternative splicing in this region of the NFl gene. In addition to the already published
sequence (type I), an alternative RNA carrying a 63-nucleotide insertion (type II) is present in all tissues
examined, although the relative amounts of types I and II vary. The insertion is conserved across species but
is not present in GAP, IRA], or IRA2. GenBank searches have failed to identify significant similarity between
the inserted sequence and known DNA or protein sequences, although the basic amino acid composition of the
insertion shares features with nuclear targeting sequences. Expression studies in yeasts show that despite the
partial disruption of the neurofibromin-IR4-GAP homology by this insertion, both forms of the NFI-GRD can
complement loss of IRA function. In vivo assays designed to compare the GAP activity of the two alternatively
spliced forms of the NFI-GRD show that both can increase the conversion of GTP-bound ras to its GDP-bound
form, although the insertion of the 21 amino acids weakens this effect. The strong conservation of this
alternative splicing suggests that both type I and II isoforms mediate important biological functions of
neurofibromin.
von Recklinghausen neurofibromatosis (type 1 neurofibro-
matosis, NF1) is an autosomal dominant disorder affecting 1
in 3,000 to 4,000 newborns of which 30 to 50% are estimated
as possessing spontaneous mutations (11, 27). Hallmarks of
the disorder are the presence of cafe-au-lait spots, neurofi-
bromas, axillary and inguinal freckling, Lisch nodules (iris
hamartomas), orthopedic abnormalities, and optic glioma.
The manifestations of the disorder are extremely variable,
even within the same family. A variety of other manifesta-
tions including cognitive impairment, seizures, and megalen-
cephaly, and malignancies can also be present.
The gene for NF1 was identified recently on chromosome
17 (9, 42, 44) by using the chromosome translocation break-
points of two unique NF1 patients to pinpoint the gene. The
NFl transcript was shown to be large (-13 kb) and ubiqui-
tously expressed (44). Several lines of evidence indicate that
the NF1 phenotype is caused by inactivation of the normal
gene product and that the NFl gene may be a tumor
suppressor gene: all the mutations identified within the gene
so far (translocations [42, 44], deletions [41, 42], point
mutations [8], and a de novo insertion [43, 44]) are consistent
with an inactivation mechanism. Furthermore, an NF1 pa-
tient with a deletion of part of proximal 17q including the
NFl gene, in which the deleted fragment exists as a mini-
* Corresponding author.
chromosome, has been identified (2). The fact that the
minichromosome is lost constitutionally from 6% of somatic
cells, leaving those cells hemizygous at the NFI locus,
supports the hypothesis that the mechanism by which the
NFl gene functions is actually recessive at the cellular level
(2). Even more supportive of the tumor suppressor hypo-
thesis is the documentation of homozygous inactivation of
the NFl gene in a malignant nerve sheath tumor from an
NF1 patient (20). Somatic mutations have also been found in
the NF1 gene in colon adenocarcinoma, astrocytoma, and
peripheral blood from patients with myelodysplastic syn-
drome (21). Further evidence in support of the hypothesis
that NFI is a tumor suppressor gene is the finding that
malignant neurofibrosarcoma cells do not produce functional
full-length neurofibromin (7). The fact that the NF1 gene is
expressed in all tissues analyzed so far by RNA polymerase
chain reaction (PCR) (44) suggests that other gene products
interact with neurofibromin to define the predilection of the
disease for the neural crest.
Initial analysis of the carboxy-terminal portion of the NF1
gene failed to show homology with known DNA or protein
sequences. cDNA walking efforts have since resulted in
cloning of the entire NF1 transcript coding region (23, 47),
resulting in demonstration of homology between the NF1
protein and mammalian ras GTPase-activating protein
(GAP) and also with the yeast equivalents Iralp and Ira2p
(inhibitory regulators of the RAS-cyclic AMP pathway) (4,
487
Vol. 13, No. 1
 o
n
 April 19, 2012 by M
AIN LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
488 ANDERSEN ET AL.
0 1000
nucleotides
2000 3000 4000 5000 6000 7000 8000
I Il Ili IlIffI I
I
2 3A 3B
NFI GAP-related domain
FIG. 1. The translated region and the GAP-related
NF1 gene. Shown to scale in the upper part of tho
translated region of the NFI gene, with the filled recta
the GAP-related domain (NFJ-GRD). Below, nucle
4823 (23) encompassing the NFI-GRD are shown iI
fashion. The filled rectangles labeled 1 through 3B coI
blocks of sequence homology between neurofibromin
and GAP (45). The arrows indicate the positions of th
to amplify by PCR a region of the NFI-GRD, as de
text.
47). Further extensive quantitative sequence
neurofibromin, GAP, and the Ira proteins has
homology blocks common to neurofibromin.
Ira2p (4). Of these 17 blocks, only 4 show homc
as well (45) (Fig. 1), thereby narrowing the es
GAP catalytic domain. This GAP-related domai
gene product has been named NFJ-GRD.
In Saccharomyces cerevisiae, Iralp and I
volved in the regulation of the RAS signal
pathway controlling cell growth and differentia
Iralp and Ira2p are both capable of catalyzing
sion of yeast RAS-GTP to RAS-GDP; in fact,
function has been demonstrated to lie in a 38
central domain of Ira2p, which closely.correl;
region of sequence homology between GAP an
min (35). This domain of both GAP and neurofit
to complement yeast ira mutant strains as s]
observation that expression of this domain
neurofibromin in iral and ira2 mutants suppre
shock sensitivity phenotype characteristic of t
The catalytic domains of GAP and neurofibron
been shown to stimulate GTPase activity of wilc
Ha-ras protein when both are expressed in yem
46) or in a baculovirus system (24).. Neith
neurofibromin appears to be able to catalyze GI
of mutant Ha-rasval-l2 in biochetnical assays
though neurofibromin differs from GAP in t
induce temperature sensitivity when overexpr
tant cdc25 Ha-rasval12 strains, suggesting tha
min carries some ability to inhibit mutant Ha-
tein (4).
We have previously reported preliminary
unexpected alternative splicing involving the A
and two other reports have provided evidence fi
expression of the two types of the NFl -GRD
undifferentiated versus differentiated neuronal
in brain tumors versus normal brain tissue (33). In this
report, we demonstrate that this alternative splice is unique
to NF1 but conserved widely across vertebrates and de-
scribe the results of yeast expression and GAP assays of the
alternative product, indicating that it retains GAP activity.
MATERIALS AND METHODS
RNA extraction. Extraction of total cellular RNA from the
solid tissues used for this study was performed with guani-
dinium thiocyanate followed by centrifugation through a
cesium chloride cushion (29). Cytoplasmic RNA was ex-
tracted from all the cell lines in the presence of Vanadyl
Ribonucleoside Complex (Bethesda Research Laboratories)
as previously described (8).
PCR analysis. Total RNA (0.2 ,ug) from each tissue sample
was reverse transcribed with CAT-RT, a primer 3' of the
NFI-GRD for analysis of NFI (5'-CAGCITlGGAAGTC),
or with oligo(dT) for analysis of GAP. Samples were thendfimai of the amplified by 35 cycles of PCR with 1 min at 94°C, 1 min ate fgureiS the 65°C, and 2 min at 72°C for all primers. Primers amplifying
ngle indicating the 303- and 366-bp type I/II products of the NF1 gene were
ntan expanded 5'-ATTGTGATCACATCCTCTGATTGG for the amino ter-
rrespond to the minus and 5'-ATCTAAAATCCCTGCTIFCATACGG for the
i, Iralp, Ira2p, carboxy terminus. Primers amplifying the 1,243- and
ie primers used 1,306-bp products of the NFl region were 5'-CATCAAGCT
-scribed in the TGTGCGCAAACAGGTGGCAGGAAAC for the amino ter-
minus and 5'-CATGCCGCGGTCAGTGTGTATCTGCCA
CAGGTITG for the carboxy terminus. These latter primers
included either a HindIII site (amino terminus) or a SacII
analysis of site (carboxy terminus) plus an additional 4 bp at the 5' end
revealed 17 for digestion and cloning purposes. Primers amplifying the
Iralp, and 243-bp product of GAP were 5'-AACATAClTTCAGAGCT
)logy to GAP TGTGGAG for the amino terminus and 5'-CAGTGTTCT
,timate of the TGCAGCAATAGGAGA for the carboxy terminus. These
in of the NFl primers were placed in regions of GAP with 100% identity
between the human and the bovine sequence (39).
Ira2p are in- Sequence analysis. Double-stranded sequencing of the
tratisducjion PCR products cloned into pBluescript was performed by the
ation (34-36). dideoxy chain termination method (30) with the Sequenase
g the conver- kit, version 2 (United States Biochemical Corporation).
this catalytic Yeast media, manipulations, and nomenclature. Saccharo-
;1-amino-acid myces cerevisiae yeast strains were grown in YPD (2%
ates with the peptone, 1% yeast extract, 2% glucose) or in synthetic
Id neurofibro- medium (0.67 g of yeast nitrogen base per liter, 2% glucose,
)romin is able and appropriate auxotrophic supplements). Standard yeast
hown by the genetic methods were followed as described previously (32).
of GAP or The lithium acetate method was used for transformation of
sses the heat yeast cells (18). Wild-type alleles and dominant mutations
hese strains. are denoted by capital letters, recessive mutations are given
nin have also in lowercase italicized letters, and gene disruptions are
d-type human shown by lowercase letters, which represent the disrupted
asts (4, 5, 35, gene, followed by two codons and the auxotrophic gene
ter GAP nor marker used for the disruption. Gene disruptions are abbre-
[Pase activity viated by lowercase italicized letters representing the mu-
(4, 25, 35), tated gene.
)eing able to Plasmids. The type I and II 303- and 366-bp PCR products
ressed in mu- from human, mouse, and chicken NFl RNA were directly
it neurofibro- cloned into pBluescript by the T-vector approach (22).
-rasVal2 pro- Sequences of the clones were determined by dideoxy se-
quencing of both strands.
evidence for The 1,306-bp NFJ-GRD was amplified by PCR with prim-
IFJ-GRD (1), ers containing HindIII (amino terminus) and SacII (carboxy
or differential terminus) sites and initially cloned into pBluescript for
transcripts in blue-white color selection. Four individual PCR clones were
cells (26) and subsequently digested with HindIIl and SacII and ligated
I I
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with the yeast expression vector pADANS, cut with the
same enzymes, thereby creating pADANS-NF1-5, -6, -12,
and -19. The vector pADANS (4) is a derivative of pADNS
(10). It contains the LEU2 gene, a HpaI-HindIII fragment
from the 2 p.m circle including the origin of replication, a
SspI-EcoRI fragment containing the ampicillin resistance
gene from the plasmid pUC18, a EcoRI-HindIII fragment
containing the promoter and the first 14 codons of the S.
cerevisiae ADH1 gene, and a HindIII-BamHI fragment
containing the ADHI terminator sequences. A polylinker
containing unique HindIII and SacII sites separates the
promoter and the terminator.
The plasmid pADGAP contains the entire coding region of
the human GAP gene on a high-copy-number LEU2 plasmid
containing the ADH1 promoter and terminator sequences,
pAD4A (5). The YepPDE2 plasmid contains the yeast PDE2
gene on a high-copy-number LEU2 plasmid, YEp13 (31).
The PDE2 gene encodes a high-affinity cyclic AMP phos-
phodiesterase.
The plasmid plF7 was constructed by inserting a BamHI
fragment that contains the human Ha-ras cDNA into the
vector PGK2F5. The BamHI fragment containing the Ha-ras
cDNA was obtained by digesting the plasmid pAHRG-H1 (5)
with the HindTII enzyme, adding BamHI linkers, and cloning
into the BgiII site of the PGK2F5 plasmid. The plasmid
plF12.9 was constructed in the same way as plF7, except
that it contains the mutant Ha-rasvall2 isolated form the
plasmid pAHRV-H2 (5). The PGK2F5 plasmid contains the
TRPI gene, the URA3 gene, and the phosphoglycerokinase
(PGK) promoter followed by a BglII site used for cloning
purposes and also contains the terminator sequences of the
PGK gene. The PGK2F5 plasmid was constructed as fol-
lows: a BglII-SphI fragment from plasmid Yrp7 (40) contain-
ing the TRPI gene without the adjacent autonomously rep-
licating sequence (ARS) sequence was cloned into the
BamHI-SphI sites of PGKYi2, creating PGK2F5. PGKYi2
was constructed by inserting the HindIII fragment of plas-
mid pEMBLYe3O/2 containing a PGK promoter-terminator
cassette (6) in the HindIIl site of plasmid pEMBLYi31 (3).
Yeast strains. The yeast strain IR2.53 (MA Ta his3 leu2
ura3 trpl ade8 iral::HIS3 ira2::ADE8) containing disrup-
tions in the IRAI and the IRA2 genes was constructed in two
steps. First, the IRA2 gene was disrupted as previously
described (4) by using a BamHI fragment containing the
ADE8 gene as an auxotrophic marker. This results in a
deletion of the 5' coding sequences of the IRA2 gene as well
as the catalytic domain. To carry out gene replacement
experiments, the yeast haploid auxotrophic strain SP1 was
transformed with a Sail-digested plasmid containing the
deleted IRA2 gene, and transformants were selected for
adenine prototrophy. The resulting strain, IRA2.5 (AMTa
his3 leu2 ura3 trpl ade8 ira2: ADE8) was transformed with
an XbaI fragment containing a deletion in the IRAI gene. In
this plasmid (5), the HIS3 gene is inserted into the BglII sites
of the IR41 gene. This results in a 3.2-kb deletion that
includes the catalytic domain of IRAI, leaving the 5' coding
sequences intact. The resulting transformants were selected
for histidine prototrophy. Southern hybridization analysis
was used to verify that both the IRAI and the IRA2 genes
were replaced by the disrupted genes.
The yeast strains J1041F7 (MA Ta his3 leu2 ura3 trpl ade8
pde2::HIS3 trpl::pTRP1 URA3 Ha-ras) and J1041F12
(MATa his3 leu2 ura3 trpl ade8 pde2::HIS3 trpl:.pTRP1
URA3 Ha-rasva`12) were constructed by transforming the
strain J104 (MATa his3 leu2 ura3 trpl ade8pde2::HIS3) (25)
with the plasmids plF7 and plF12.9, respectively, after
digestion with the enzyme XbaI, selecting for uracil pro-
totrophy. This leads to the integration of the plasmid into the
TRPJ locus.
Heat shock sensitivity assay. Heat shock sensitivity was
determined as described previously (31, 37). Yeast strains
were transformed with various plasmids containing the
LEU2 gene and plated onto SC-Leu (synthetic complete
minus Leu) plates. Independent transformants were patched
onto SC-Leu plates and incubated at 30°C for 2 days. Heat
shock was performed by replica plating cells to a plate
preheated for 1 h at 55°C and then by a 10-min incubation at
55°C. After heat shock treatment, the plates were incubated
at 30°C for 2 days and photographed.
GAP assays and quantitation. Yeast strains were grown to
saturation in 5 ml of selective media and then diluted in 200
ml of YPD media. Cultures were grown for 12 h, and cells
were harvested by centrifugation. Cell pellets were resus-
pended in buffer A (20 mM Tris-HCl [pH 7.5], 50 mM NaCl,
5mM MgCl2) with 1% Nonidet P-40, 1 ,g (each) of aprotinin
and pepstatin per ml, and 1 mM phenylmethylsulfonyl fluo-
ride. The cells were lysed by vortexing in Eppendorf tubes
containing glass beads. The lysates were centrifuged for 2
min at 4°C in an Eppendorf centrifuge, and the supernatant
was used in the GAP assays.
GAP assays were performed as reported elsewhere (38).
Purified Ha-rasp2l (0.07 ,uM) (16) was prebound to GTP
by incubation for 30 min at 30°C in buffer B (20 mM Tris-
HCl [pH 7.5], 20 mM NaCl, 2.5 mM MgCl2) with 0.025
,uM [a-32P]GTP (3,000 mCi/mmol; New England Nuclear),
1 mM ATP, and 1 mg of bovine serum albumin per ml in a
volume of 40 pul. The cell lysates, 0.4 mg in 20 .lI, were
incubated with 1 ,ul of p21 prebound to GTP for 30 min at
room temperature. The samples were then diluted to 200 pI
with buffer A and incubated for 30 min at 4°C with 2 ,ug
of monoclonal antibody Y13-259 (13) followed by incubation
with rabbit anti-rat immunoglobulin and protein A-Seph-
arose for 1 h at 4°C. Immunoprecipitates were washed with
buffer A, and the nucleotides were eluted from p21 by
incubation with 10 p.l of 1% sodium dodecyl sulfate (SDS)
and 20 mM EDTA for 5 min at 65°C. A total of 2 ,ul of eluted
nucleotides was resolved by chromatography on polyethyl-
eneimine-impregnated cellulose plates in 0.75 M KH2PO4,
pH 4.0. The chromatography plates were subjected to auto-
radiography, and the labeled nucleotides were scraped off
the plates and counted in scintillation fluid.
Analysis of the guanine nucleotide bound to RAS. The
analysis was performed essentially as previously described
(14). Yeast cells expressing human Ha-ras under the control
of the PGK promoter (strain J1041F7) were grown to anA6.
of 0.6 to 1.0 in selective media. Cells were collected and
incubated in 10 ml of SD-P media with 1 mCi of 32p;
(NEN-Dupont) for 3 h. The cultures were collected by
centrifugation and washed once with 40 ml of water. The
pellets were resuspended in 1 ml of cold lysis buffer contain-
ing 50 mM Tris-HCl (pH 7.4), 20 mM MgC12, 100 mM NaCl,
0.5% (vol/vol) Nonidet P-40, 1 mM phenylmethylsulfonyl
fluoride, and 1 p.g (each) of leupeptin and aprotinin per ml
and disrupted by vortexing with glass beads. The lysates
were centrifuged for 15 min at 4°C in an Eppendorf centri-
fuge, and the supernatants containing 1.0 x 108 cpm of
trichloroacetic acid-insoluble radioactivity were subjected to
immunoprecipitation as described above for the GAP as-
says. The nucleotides were eluted and resolved as described
above, and the chromatography plates were exposed to
X-ray film for quantitation by densitometry (Bioimage Cor-
poration, Ann Arbor, Mich.) or direct quantitative measure-
VOL. 13, 1993
 o
n
 April 19, 2012 by M
AIN LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
490 ANDERSEN ET AL.
ment with the Fujix BAS2000 Bio-imaging Analyzer. The
percent GTP of total guanine nucleotides was calculated
from these analyses by assuming uniform 32P labeling of all
phosphates and by correcting for the moles of phosphate per
mole of guanosine.
RESULTS
PCR of the NFI-GRD. By using RNA PCR with primers as
indicated in Fig. 1, an alternative product involving the
NFI-GRD was identified. In addition to amplification of the
expected 303-bp product (type I) according to the known
sequence (23, 47), a larger band (type II) was seen when
RNA from several normal and pathologic human tissues
including kidney, spleen, lung, colon, muscle, brain, periph-
eral nerve, an Epstein-Barr virus-transformed lymphoblas-
toid cell line, HeLa cells, and a melanoma cell line as shown
in Fig. 2A was amplified. This was also observed in RNA
from stomach, skin fibroblasts, HepG2 (hepatoma cell line),
HEL (erythroleukemia cell line), HT29 (colon cancer cell
line), NF88-3 (neurofibrosarcoma cell line), neuroblastoma,
thymoma, breast carcinoma, and neurofibroma (data not
shown). Some variation in the relative amounts of types I
and II was seen from tissue to tissue. However, the quanti-
tative significance of this variation is uncertain, since some
variation also was seen when the reverse transcription and
PCR reaction of the same RNA sample were repeated.
Subsequent PCR of reverse-transcribed RNA from mouse,
chicken, rat, and bovine sources showed a similar additional
larger product (Fig. 2B). The successful amplification of
cDNA from such diverse species with PCR primers derived
from the human sequence is an indication of the high degree
of evolutionary conservation of this domain of NFl.
Sequence analysis of type II NFI-GRD. The larger ampli-
fied products from human lung, kidney, and an Epstein-Barr
virus-transformed lymphoblastoid cell line were cloned into
pBluescript. Sequence analysis (Fig. 3) of two individual
clones from each tissue sample showed that in all of them, an
in-frame insertion of 63 bp was present at nucleotide position
3108 (47) or position 4321 (23). This places the insertion in
block 2, a region of strong homology between GAP, Iralp,
Ira2p, and neurofibromin (45). In fact, the insertion signifi-
cantly weakens the statistical significance of this homology
block. Thirty-three of 63 nucleotides are adenine, and thus
the inserted protein sequence is rich in basic amino acids,
with 5 of 21 amino acids being lysine and 1 being histidine.
Comparison of this DNA and protein sequence with the
entries in GenBank failed to show significant similarity with
known sequences. The additional sequence (1,243 bp [see
below]) of the RNA PCR product surrounding the inserted
63 bp of the type II product showed a perfect match with the
published type I sequence. Furthermore, an oligomer corre-
sponding to the inserted 63 bp was shown to hybridize to a
-500-kb yeast artificial chromosome containing the entire
NFI catalytic region (data not shown), indicating that the
inserted exon arises from this same locus. Taken together,
this indicates that the type II RNA originates from the same
locus by alternative splicing and is not the product of a
different locus.
Similarly, the PCR-amplified type I and II products from
mouse and chicken cDNAs were cloned into pBluescript,
and two individual clones from each were sequenced. Out-
side the insertion, the mouse and chicken sequences show
strong homology to that of humans (mouse, 93.7%, and
chicken, 84.5%). Both show an insertion of 63 bp in the type
II form at the same nucleotide position and with an almost
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FIG. 2. (A) RNA PCR identifies two alternative products of the
NFJ-GRD. RNA from several human tissues was reverse tran-
scribed with CAT-RT, a primer 3' of the NFJ-GRD, and submitted
to 35 cycles of PCR (1 min at 94°C, 1 min at 65°C, and 2 min at 720C)
with the primers shown in Fig. 1. In all tissues examined, two PCR
products were present, one at the expected size of 303 bp and the
other at 366 bp. The larger band in some lanes is presumed to be a
heteroduplex. When the reverse transcription and the PCR of the
same RNA samples were repeated, different amounts of the two
products were seen, thereby making comparison of the relative
amounts of the two products between different tissues difficult. No
bands were seen when DNA was amplified (lane 13), suggesting that
the primers are located in two different exons separated by a
significant distance. The marker lane (lane 1) contains the HaeIII
fragments of 4X174 RF DNA (Bethesda Research Laboratories).
(B) The alternative form of the NFI-GRD is conserved across
species. RNA from human brain, rat PC12 pheochromocytoma
cells, mouse kidney, chicken brain, and bovine choroid plexus
(lanes 2 to 6) was reverse transcribed with CAT-RT and submitted to
PCR as for panel A. Again, two PCR products were seen, showing
that the identified alternative splicing is conserved across species.
The fact that both the reverse transcription primer and the two PCR
primers are designed from the known human sequence and yet still
are able to amplify cDNA from other species under relatively
stringent conditions is indicative of a high degree of nucleotide
conservation among the different species. In another experiment,
RNAs from human leukocytes and bovine retina (lanes 9 and 10)
were reverse transcribed with oligo(dT) and submitted to PCR with
primers flanking the potential site of a similar insertion in the GAP
gene (35 cycles, 1 min at 94°C, 1 min at 65°C, 2 min at 72'C). This
time only a PCR product of 243 bp, the expected size according to
the published sequence (39), was seen. Included in each experiment
were DNA and water controls.
A E0
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FIG. 3. Position and sequence of the inserted 63 nucleotides.
Sequence analysis showed that an in-frame insertion of 63 nucle-
otides is present in type II RNA at nucleotide position 4321 of the
NFI gene (23). This places the insertion in block 2 as indicated. The
sequence shows strong conservation across species.
identical nucleotide composition as in humans (Fig. 3). In
mouse sequences there is an A-to-G substitution at nucle-
otide position 44 within the insertion resulting in a conser-
vative lysine-to-arginine substitution in the protein product.
In chicken sequences, two silent nucleotide substitutions are
present.
PCR analysis of the GAP catalytic domain. The genomic
sequences of yeast IRAI and IRA2 are known and are
colinear with the cDNAs, thereby providing evidence that
such an alternative isoform does not occur in either of these
genes (34, 36). To determine whether such an alternative
product was present in GAP, we designed GAP-specific
primers flanking the predicted site of the insertion (39). RNA
PCR revealed only one band of the expected size in both
human and bovine RNA (Fig. 2B), indicating that the occur-
rence of alternative splicing in this conserved domain is
unique to NFI.
Construction of the NFl expression vector. To obtain data
regarding the functional significance of the 63-bp insertion in
the NFJ-GRD, we amplified by PCR a region from Epstein-
Barr virus-transformed lymphoblastoid cDNA containing
the complete NFJ-GRD from amino acids 1124 to 1538 (23).
The type II product was cloned into pBluescript, and four
independent PCR clones were subsequently subcloned into
the yeast expression vector pADANS, giving rise to
pADANS-NF1-5, pADANS-NFl-6, pADANS-NF1-12, and
pADANS-NF1-19. Complete sequencing of the inserts of
two of the four clones (pADANS-NF1-5 and pADANS-NF1-
19) showed a nucleotide difference at position 3491 of one of
the published sequences (47) in both clones, which results in
an amino acid change from alanine to glycine. This C-to-G
change is in full agreement with the sequence obtained in our
laboratory from a type I cDNA clone isolated from a fetal
brain library (Stratagene, catalog number 936206) (23) and
may therefore reflect either an error in the original published
sequence or a polymorphism. Likewise, at nucleotide posi-
tion 2547 (47) a silent nucleotide change from C to G was
present in pADANS-NF1-5, in pADANS-NF1-19, and in
two type I cDNA clones isolated from the fetal brain library.
The sequence was otherwise in agreement with the pub-
lished sequence and demonstrated the 63-bp insertion.
Complementation of ira mutant strains by NFI-GRD types
IR-2.53 Control
(iral-, ira2-) NFI type I
NFl type II
GAP
J1041F7 Control
(Ha-ras, pde2-) NFl type I
NFl type II
GAP
PDE2
D
J1041F12
(Ha-ras , pde2-)
Control
NFl type I
NFl type II
GAP
PDE2
-
__s
s___
___
C3=3
-_s___
-
CONTROL 55'C HEAT SHOCK
FIG. 4. Effects of expressingNFJ-GRD type I and type II on the
heat shock sensitivity of strains lacking the IRA1 and the IRA2
genes and strains expressing wild-type or activated human ras
genes. Yeast strains (see Materials and Methods) were transformed
with plasmids containing the LEU2 gene and selected on SC-Leu
plates. Independent transformants were patched onto SC-Leu plates
and incubated at 30°C for 2 days, replica plated onto SC-Leu plates,
and heat shocked at 55°C for 10 min. After heat shock treatment, the
plates were incubated at 30°C for 2 days. The strains were trans-
formed with a control plasmid, pADANS; a plasmid containing the
NFI-GRD type I catalytic fragment, pADANS-NF1 type I; a
plasmid expressing the NFl-GRD type II, pADANS-NF1 type II; a
plasmid expressing the entire coding sequence of the human GAP
gene, pADGAP; or a plasmid expressing the phosphodiesterase
gene PDE2, YepPDE2.
I and II. As mentioned in the Introduction, the IRAI and
IRA2 gene products of S. cerevisiae downregulate RAS
activity by stimulating its GTPase activity. Deletion of either
IRA1 or IRA2 results in sensitivity to heat shock like that of
yeast cells expressing RAS2vatl9. It has been previously
shown that GAP and the catalytic domain of neurofibromin
(type I) are both able to complement loss of IRA function
and suppress the heat shock sensitivity phenotype when
expressed in ira mutant strains (4, 5, 24, 35, 46). On the other
hand, neither GAP nor the type I NFJ-GRD can inhibit the
mutationally activated RAS2 al19, as indicated by lack of
suppression of the heat shock sensitivity. In this yeast strain,
only expression of the PDE2 gene, which encodes the
high-affinity cyclic AMP phosphodiesterase, can suppress
the heat shock sensitivity phenotype.
To determine if the 21-amino-acid insertion has an effect
on the activity of the NFJ-GRD, we tested for the ability of
NFJ-GRD type II to suppress the heat shock sensitivity
phenotype of ira mutant strains. As shown in Fig. 4, both
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492 ANDERSEN ET AL.
NFJ-GRD type I and II, like human GAP, suppress the heat
shock sensitivity of an iral (Fig. 4A) as well as an iral ira2
mutant strain (Fig. 4B).
We have previously shown that both the catalytic domain
of neurofibromin (type I) and human GAP can inhibit the
wild-type human Ha-ras when expressed in yeasts, while
only NFJ-GRD type I is capable of inhibiting the mutant
Ha-rasval12 protein (4, 5). To determine if the NFJ-GRD
type II can also inhibit the function of human Ha-ras
expressed in yeasts, we tested for its ability to suppress the
heat shock sensitivity phenotype of yeast strains expressing
the wild-type Ha-ras (Fig. 4C) or the activated Ha-rasvali2
mutant (Fig. 4D). The strains J1041F7 and J1041F12 are
derived from strain J104, which has a disruption in the
phosphodiesterase gene PDE2. This strain is not sensitive to
heat shock. When human wild-type Ha-ras (Fig. 4C, Con-
trol) or human activated Ha-ras va-12 mutant (Fig. 4D, Con-
trol) are integrated in the TRP1 locus under the control of the
PGK promoter (see Materials and Methods), these strains
become heat shock sensitive. The heat shock sensitivity of
both strains (J1041F7 and J1041F12) can be suppressed by
the phosphodiesterase gene PDE2 (Fig. 4C and D, PDE2). In
addition, human GAP and both NFJ-GRD type I and II are
able to suppress the heat shock sensitivity phenotype of the
yeast strain expressing the human wild-type Ha-ras (Fig.
4C). Both NFJ-GRD type I and type II are as efficient in
suppressing the heat shock sensitivity phenotype of the
strain that expresses the activated Ha-rasval12 mutant. In
contrast, GAP is unable to suppress the function of the
activated mutant Ha-rasval-l2 in this strain (Fig. 4D).
GAP assays of yeasts expressing NFI-GRD type I or type II.
We have shown previously that lysates prepared from cells
expressing the type I NFJ-GRD protein stimulate the
GTPase activity of human wild-type Ha-ras, although to a
lesser extent than human GAP (4). Lysates from yeasts
expressing GAP or NFJ-GRD type I are not capable of
accelerating the hydrolysis of GTP by the activated human
Ha-rasva l2. In order to compare the GTPase-stimulating
activity of the two alternative forms of the NFJ-GRD, we
prepared lysates from an iral ira2 mutant strain (strain
IR2.53; see Materials and Methods) transformed with either
a control plasmid or plasmids expressing NFJ-GRD type I,
NFJ-GRD type II, or human GAP and tested these for their
abilities to increase the GTPase activity of purified human
wild-type Ha-ras. As shown in Table 1, compared with
control lysates, GTP hydrolysis was increased by incubation
of Ha-ras with 0.4 mg of lysates from yeasts expressing GAP
or NFJ-GRD type I. In contrast, lysates prepared from
yeasts expressing NFJ-GRD type II were not capable of
increasing the GTPase activity of Ha-ras. In lysates pre-
pared from yeasts expressing GAP or NFJ-GRD type I,
some increase in GTPase activity of Ha-ras is still detected
even when only 0.04 mg of total protein is assayed. Western
blot (immunoblot) analysis with a polyclonal antibody raised
to a peptide derived from the published sequence (17)
showed that the difference in the ability of the extracts to
stimulate the GTPase activity is not due to a difference in the
amount of NFI-GRD protein expressed, since both extracts
from each independent experiment contain the same amount
of NFJ-GRD (data not shown).
In vivo determination of the amount of Ha-ras bound to
GTP in radiolabeled yeast cells expressing NFI-GRD type I
and type II. As shown in Table 1, yeast extracts prepared
from strains expressing NFI-GRD type II show no detect-
able GTPase-stimulating activity. To determine if the inabil-
ity of the NFI-GRD type II to increase the GTPase activity
TABLE 1. Ha-ras GTPase stimulation by yeast lysatesa
Expt" and Proportion of p2lras bound to GTP
protein (mg) Control NF1 type I NF1 type II GAP
1
0.04 0.63 0.52 0.63 0.51
0.40 0.64 0.23 0.60 0.14
2
0.04 0.62 0.58 0.64 0.44
0.40 0.65 0.16 0.65 0.10
a Wild-type human Ha-ras protein prelabeled with [32P]GTP was incubated
for 30 min at room temperature with either 0.04 mg or 0.4 mg of yeast extracts
of the iral ira2 mutant yeast strain IR2.53 transformed with the control
plasmid pADANS; the plasmid expressing the NFJ-GRD type I, pADANS-
NF1 type I; the plasmid expressing the NFI-GRD type II, pADANS-NF1
type II; or the plasmid expressing the human GAP gene, pADGAP. The
Ha-ras protein was then immunoprecipitated with the monoclonal antibody
Y13-259 and incubated with rabbit anti-rat immunoglobulin and protein
A-Sepharose. The labeled nucleotides were eluted and resolved by thin-layer
chromatography (see Materials and Methods). The chromatography plates
were subjected to autoradiography and the spots were scraped and counted in
scintillation fluid.
b Two separate experiments were performed with independently prepared
lysates.
of Ha-ras in vitro is also reflected in intact cells, we
determined the amount of Ha-ras bound to guanine nucle-
otides in strains expressing the wild-type human Ha-ras
under the control of the PGK promoter (J1041F7) and
transformed with a control plasmid or plasmids expressing
the NF1-GRD type I and type II, GAP, or the phosphodies-
terase gene PDE2 (Fig. 5; Table 2). Cell extracts from the
yeast strains were prepared, Ha-ras protein was immunopre-
cipitated, and the guanine nucleotide bound to Ha-ras was
analyzed as described in Materials and Methods (Fig. 5;
Table 2). The autoradiogram in Fig. 5 shows that in intact
cells expressing the NF1-GRD type I or type II, the amount
of human Ha-ras bound to GTP is reduced compared with
either the control strain or the strain expressing the PDE2
gene. In addition, expression of human GAP also leads to a
decrease in the GTP-bound Ha-ras, as has been previously
GDP |1
GTP|
1 2 3 4 5
FIG. 5. Autoradiograph of the guanine nucleotides bound to
Ha-ras in strains expressing NFI-GRD type I and type II. Yeast
strains expressing wild-type Ha-ras under the PGK promoter (strain
J1041F7 [see Materials and Methods]) and transformed with
pADANS, the control plasmid (lane 1), pADANS-NF1 type I (lane
2), pADANS-NF1 type II (lane 3), pADGAP (lane 4), and YepPDE2
(lane 5) were labeled with 32p; for 3 h, and Ha-ras was immunopre-
cipitated as described under Materials and Methods. The labeled
nucleotides were eluted and resolved by thin-layer chromatography.
Shown is the autoradiograph of the plate exposed to X-ray film;
results of the quantitation of the plate are shown in Table 2,
experiment 1.
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TABLE 2. Guanine nucleotide bound to Ha-ras in yeast cellsa
Proportion of protein bound with GTP
Expt
PDE2 Vector GAP NF1 type I NF1 type II
lb 0.51 0.39 0.13 0.02 0.13
2 0.34 0.27 0.07 0.04 0.03
3 0.26 0.11 0.00 0.06
4 0.27 0.14 0.00 0.09
5 0.26 0.05 0.01 0.05
Avg 0.29 0.10 0.01 0.07
a Human Ha-ras was immunoprecipitated from radiolabeled yeast cells
transformed with the phosphodiesterase gene PDE2, the vector plasmid, NF1
type I, NF1 type II, or human GAP, respectively, as described in the legend
to Fig. 5 and Materials and Methods. The bound guanine nucleotides were
eluted and resolved by thin-layer chromatography. The chromatography
plates were exposed to X-ray film for quantitation by densitometry (experi-
ments 1 and 2) or direct quantitative measurement with the Fujix BAS2000
Bio-imaging Analyzer (experiments 3 to 5). The results are presented as the
proportion of total counts recovered as GTP from the Ha-ras proteins. The
difference between NF1 type I and NFl type II is significant at the P = 0.05
level (two-tailed Student's t test for paired varieties).
b The autoradiograph shown in Fig. 5 is derived from this experiment.
shown (35). That the reduction of the amount of GTP-bound
Ha-ras is dependent on the expression of proteins that have
GTPase-stimulating activity and not proteins that in general
suppress the heat shock sensitivity phenotype of this strain
is shown by the amount of GTP-bound Ha-ras in strains
transformed with the phosphodiesterase gene PDE2, which
is comparable to that of the control strain (Table 2). In
contrast to the results obtained in vitro, the results in Table
2 show that compared with the control and the strain
expressing PDE2, the amount of GTP-bound Ha-ras is
reduced in intact cells expressing the NFI-GRD type I, type
II, and GAP, suggesting that in vivo the type II NFl-GRD
might have GTPase-stimulating activity. In analyzing the
results of five independent experiments, cells expressing the
NFJ-GRD type II have consistently more Ha-ras bound to
GTP than cells expressing NFJ-GRD type I.
DISCUSSION
Multiple examples of alternative splicing have been de-
scribed previously in the eukaryotic molecular biology liter-
ature (19). The combinatorial advantages of shuffling exons
in and out of a protein product and the opportunity to utilize
one gene for several different functions have been noted,
although in only a few instances is definitive information
available about the precise functions of alternatively spliced
products of the same gene. The development of the PCR and
its application to RNA analysis will undoubtedly expand the
recognition of the alternative splicing process, since it facil-
itates the identification of small differences in transcripts
which would be more difficult to detect by Northern (RNA)
blotting.
The NFl gene is large and complex, stretching across
approximately 300 kb of genomic DNA (23), encoding a
transcript of 13 kb (44), and made up of a large number of
exons, the boundaries of most of which have not yet been
completely identified. One other potential example of alter-
native splicing of NFI has previously been identified near
the carboxy-terminal end by the comparison of two cDNA
clones (9). The alternative splice event described in this
report, however, is of particular interest because it falls
within a central domain of the NFI molecule where there is
the most information about function, namely, the catalytic
domain responsible for stimulating conversion of ras-GTP to
ras-GDP. The catalytic activity of this domain of neurofibro-
min has been previously postulated by sequence compari-
sons and subsequently confirmed by genetic and biochemical
experiments (4, 24, 46, 47). It is fair to say, however, that
this is unlikely to be the only function of neurofibromin, as
the protein itself is quite large (2,818 amino acids), and this
catalytic function can be expressed by using only about 10%
of the coding region from the central portion of the molecule.
Demonstration of colocalization of neurofibromin with mi-
crotubules suggests an additional possible role for the NFl
gene product in intracellular signal transduction pathways
(15a). Of further note is the significant additional homology
between neurofibromin, Iralp, and Ira2p on the carboxy-
terminal side of this catalytic domain, which implies an
evolutionarily shared additional function, the nature of
which remains elusive. An attractive option would be that
this part of the molecule is responsible for some sort of
effector function.
The additional 63 bp in the type II transcript undoubtedly
reflects the insertion of a separate exon by alternative
splicing. The striking evolutionary conservation of the type
II form, which is true both for the precise positioning as well
as the sequence of the encoded 21 additional amino acids,
strongly supports the conclusion that the presence of both of
these two forms is functionally important. Sequence analysis
of the effect of this insertion on the homology between NFl
and other GAPs suggested that the type II form might no
longer possess biological activity. This conclusion has been
ruled out by the yeast expression experiments and analysis
of the guanine nucleotide bound to Ha-ras in yeast cells. In
heat shock assays, the NF1 type I and type II are both
equally effective in inhibiting the function of the yeast RAS
genes as well as the wild-type Ha-ras and mutant Ha-
rasval12 (Fig. 4). The ability of the NFl type II isoform to
inhibit the function of the mutant Ha_rasval12 suggests that
the type II product binds to this activated form with affinity
similar to that of the NFl type I, since the ability of the
NFJ-GRD to inhibit the function of activated Ha-rasvall2
does not depend on its ability to increase its GTPase activity.
However, a difference is noted in in vitro biochemical assays
of the yeast extracts expressing NFJ -GRD types I and II. In
contrast to extracts containing type I, extracts prepared
from cells expressing NF1 type II (Table 1), under condi-
tions in which there are comparable amounts of both types I
and II present, lack apparent GTPase-stimulating activity
with Ha-ras. This result suggests that the 21-amino-acid
insertion results in a decrease in the catalytic activity ofNF1
type II and it remains a formal (but unlikely) possibility that
the biological activity of the type II form derives from some
mechanism other than GTPase activation. Results from in
vivo determination of the guanine nucleotide bound to
Ha-ras in intact cells (Fig. 5 and Table 2) show that both
isoforms can decrease the amount of GTP bound to Ha-ras,
although the effect of type II is slightly lower. The discrep-
ancy between these two results might be due to the fact that
although both assays measure related functions (ras-GTP
hydrolysis), they are not equivalent. In vitro, the concentra-
tion of Ha-ras (3.5 nM) is probably much higher than the
concentration of the NFJ-GRD. Under these conditions, as
has been shown previously (24), the NFl-GRD is saturated
with respect to p21-GTP ras, so that the low activity
measured reflects the catalytic properties and not the binding
affinity. In intact cells, NFJ-GRD is expressed in a multi-
copy plasmid and under the control of theADHI promoter,
conditions which ensure high levels of expression. Under
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these conditions the NFl-GRD is probably in excess of the
amount of p2lras, and this results in an apparent increase in
the catalytic activity of the NFJ-GRD. Therefore, in the
yeast strains overexpressing NFJ-GRD, the differences in
the catalytic potencies of the NF1 type I and type II will be
minimized. Another aspect that has to be considered is that
the insertion of the 21 amino acids in the catalytic domain
can result in an increase in the binding affinity for p2lras.
Neither the in vitro assay nor the assay in intact cells allow
us to assess this possibility. Resolution of this possibility will
await a more detailed biochemical and kinetic characteriza-
tion of the two proteins.
Using RNA PCR analysis, we have not been able to detect
evidence thus far of consistent tissue specificity differences
of type I and II RNA in a variety of normal and abnormal
tissues. In fact, at least some evidence of both forms has
been found in all tissues analyzed. Interestingly, however,
one study indicates that the type I transcript is predomi-
nantly expressed in normal brain tissue, whereas the type II
transcript predominates in brain tumors (33). However,
another study indicates that the type I transcript is predom-
inantly expressed in undifferentiated cells, whereas the type
II transcript predominates in differentiated cells (25). This
group also noted a change in expression pattern in SH-SY5Y
neuroblastoma cells from predominantly type I to type II
NFJ-GRD mRNA when these cells were induced by retinoic
acid to differentiate in a neuronal direction. It is thus
conceivable that the type II mRNA, through interaction with
as yet unknown cellular molecules, functions as a switch in
cellular differentiation.
There are at least four other possible functional explana-
tions for the occurrence of the type I and type II forms and
their evolutionary conservation across at least 200 million
years. The first possibility, namely, that the insertion to
create the type II form represents a way of generating an
NFl protein without GAP catalytic function, seems to have
been ruled out by the experiments reported herein. A second
possibility is that the type I and type II catalytic domains are
qualitatively different in some important way, perhaps in the
efficiency with which they interact differently with various
members of the ras family of proteins. This will require
further investigation with K-ras, N-ras, R-ras, and K-rev-i.
A third possibility, and one which has been partially sup-
ported by the experiments here, is that there is a quantitative
difference in the catalytic function of the type I and type II
products. It should be noted that the assays we have used in
this study might not be a true reflection of the mammalian
system, in which the amounts of both proteins (ras and
neurofibromin) will be more comparable and under regula-
tory control. It is also conceivable that the analysis of the
type I and II forms might yield a different result if studied in
the full-length proteins as opposed to in the catalytic do-
mains.
A fourth possibility is that the 21-amino-acid insertion in
the type II form generates an isoform with a totally different
function in addition to its GAP activity. In this regard, it is
noteworthy that the amino acid sequence of the insertion is
highly basic and shares some sequence similarities with the
nuclear localization signals that have been defined for a large
number of proteins (12, 15, 28). It is not currently possible to
define a completely accurate consensus sequence for such
nuclear localization signals, and the proof or disproof of such
a suggestion rests with a mutational analysis and a determi-
nation of the ability of this sequence to target a heterologous
protein to the nucleus. It is certainly not clear why it would
be advantageous to target any part of neurofibromin to the
nucleus, but our present stage of knowledge about the
complete array of functions of this large protein is suffi-
ciently superficial that the notion should not be discounted.
Whichever additional function this alternative exon might
convey to the molecule, it appears to be unique to NFI when
compared with other known GAP-like molecules.
The importance of the type I and type II forms in the
pathogenesis of neurofibromatosis also remains to be eluci-
dated. In general, mutations identified thus far in the gene
have been located in the carboxy-terminal half of the pro-
tein, though this is at least in part a reflection of ascertain-
ment bias due to earlier availability of 3' cDNA sequences
(9, 43, 44). Most of these mutations would be expected to
produce truncated versions of both the type I and II iso-
forms, although these may well be unstable. It will be of
interest to look specifically for NF1 mutations in the 63-bp
alternate exon to assess the effects on phenotype. Alter-
nately, the specific disruption of the type II form by homol-
ogous recombination in mice should be feasible and might
also shed light on the relative importance and function of this
alternative form.
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